newsfilter
← Latest News
GlobeNewswire·

Jounce Therapeutics Reports Third Quarter 2021 Financial Results

- Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 - - Ended the quarter with $249.0 million in cash, cash equivalents and investments - - Company to host conference call a